Myriad Genetics (MYGN) Competitors $7.80 -0.04 (-0.51%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$7.67 -0.13 (-1.65%) As of 10/14/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MYGN vs. FOLD, CLDX, BCRX, MNKD, NVAX, OPK, DVAX, ZBIO, INVA, and GERNShould you be buying Myriad Genetics stock or one of its competitors? The main competitors of Myriad Genetics include Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), Novavax (NVAX), OPKO Health (OPK), Dynavax Technologies (DVAX), Zenas BioPharma (ZBIO), Innoviva (INVA), and Geron (GERN). These companies are all part of the "biotechnology" industry. Myriad Genetics vs. Its Competitors Amicus Therapeutics Celldex Therapeutics BioCryst Pharmaceuticals MannKind Novavax OPKO Health Dynavax Technologies Zenas BioPharma Innoviva Geron Amicus Therapeutics (NASDAQ:FOLD) and Myriad Genetics (NASDAQ:MYGN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends. Does the media favor FOLD or MYGN? In the previous week, Amicus Therapeutics had 9 more articles in the media than Myriad Genetics. MarketBeat recorded 17 mentions for Amicus Therapeutics and 8 mentions for Myriad Genetics. Amicus Therapeutics' average media sentiment score of 0.99 beat Myriad Genetics' score of 0.77 indicating that Amicus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amicus Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Myriad Genetics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, FOLD or MYGN? Amicus Therapeutics has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Do analysts prefer FOLD or MYGN? Amicus Therapeutics presently has a consensus price target of $15.78, indicating a potential upside of 96.24%. Myriad Genetics has a consensus price target of $12.45, indicating a potential upside of 59.67%. Given Amicus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Amicus Therapeutics is more favorable than Myriad Genetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amicus Therapeutics 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82Myriad Genetics 2 Sell rating(s) 9 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.13 Is FOLD or MYGN more profitable? Amicus Therapeutics has a net margin of -6.67% compared to Myriad Genetics' net margin of -47.45%. Amicus Therapeutics' return on equity of -5.07% beat Myriad Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Amicus Therapeutics-6.67% -5.07% -1.23% Myriad Genetics -47.45%-5.17%-3.44% Which has stronger valuation and earnings, FOLD or MYGN? Amicus Therapeutics has higher earnings, but lower revenue than Myriad Genetics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmicus Therapeutics$571.16M4.34-$56.11M-$0.12-67.00Myriad Genetics$832.90M0.87-$127.30M-$4.28-1.82 Do insiders and institutionals believe in FOLD or MYGN? 99.0% of Myriad Genetics shares are owned by institutional investors. 2.2% of Amicus Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryAmicus Therapeutics beats Myriad Genetics on 13 of the 17 factors compared between the two stocks. Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYGN vs. The Competition Export to ExcelMetricMyriad GeneticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$729.47M$3.35B$6.04B$10.50BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-1.8221.9084.6427.24Price / Sales0.87263.81508.12197.88Price / Cash7.8546.9537.5761.53Price / Book1.0110.4312.256.74Net Income-$127.30M-$52.58M$3.32B$276.59M7 Day Performance2.09%-1.55%-1.34%-0.47%1 Month Performance6.70%12.96%8.14%7.47%1 Year Performance-67.47%15.43%72.27%34.58% Myriad Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYGNMyriad Genetics3.5688 of 5 stars$7.80-0.5%$12.45+59.7%-68.9%$729.47M$832.90M-1.822,700News CoverageAnalyst ForecastFOLDAmicus Therapeutics4.5175 of 5 stars$8.18-1.4%$15.78+92.9%-22.8%$2.56B$528.29M-68.16480CLDXCelldex Therapeutics2.1386 of 5 stars$27.13+1.3%$43.78+61.4%-12.6%$1.78B$7.02M-9.01150News CoverageAnalyst ForecastBCRXBioCryst Pharmaceuticals4.1886 of 5 stars$7.04-2.5%$16.30+131.5%-13.9%$1.52B$450.71M-39.11530Trending NewsGap DownMNKDMannKind3.9382 of 5 stars$5.10+4.5%$10.86+112.9%-22.0%$1.50B$285.50M46.37400Analyst ForecastNVAXNovavax4.2464 of 5 stars$8.62+3.5%$12.33+43.1%-29.6%$1.35B$682.16M3.781,990News CoverageOPKOPKO Health4.3208 of 5 stars$1.51flat$2.63+73.8%+3.4%$1.20B$713.10M-6.042,997DVAXDynavax Technologies4.5707 of 5 stars$10.01+0.5%$24.33+143.1%-6.0%$1.17B$277.25M-21.76350ZBIOZenas BioPharma2.259 of 5 stars$26.54-0.2%$38.33+44.4%N/A$1.12B$5M-7.48N/ANews CoverageInsider TradeAnalyst RevisionGap DownINVAInnoviva4.8286 of 5 stars$16.94-2.4%$37.60+122.0%-16.2%$1.09B$358.71M54.65100GERNGeron2.4909 of 5 stars$1.27-3.1%$3.79+198.1%-70.0%$835.80M$76.99M-9.7770News Coverage Related Companies and Tools Related Companies FOLD Alternatives CLDX Alternatives BCRX Alternatives MNKD Alternatives NVAX Alternatives OPK Alternatives DVAX Alternatives ZBIO Alternatives INVA Alternatives GERN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYGN) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
